001     836178
005     20220930130128.0
024 7 _ |a 10.1002/jnr.24110
|2 doi
024 7 _ |a 0360-4012
|2 ISSN
024 7 _ |a 1097-4547
|2 ISSN
024 7 _ |a pmid:28695985
|2 pmid
024 7 _ |a WOS:000425811000009
|2 WOS
024 7 _ |a altmetric:23450471
|2 altmetric
037 _ _ |a FZJ-2017-05301
082 _ _ |a 570
100 1 _ |a Wedekind, Franziska
|0 P:(DE-Juel1)131711
|b 0
|e Corresponding author
245 _ _ |a Intrastriatal administration of botulinum neurotoxin A normalizes striatal D$_{2}$R binding and reduces striatal D$_{1}$R binding in male hemiparkinsonian rats
260 _ _ |a New York, NY [u.a.]
|c 2018
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1517838759_21914
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cerebral administration of botulinum neurotoxin A (BoNT-A) has been shown to improve disease-specific motor behavior in a rat model of Parkinson disease (PD). Since the dopaminergic system of the basal ganglia fundamentally contributes to motor function, we investigated the impact of BoNT-A on striatal dopamine receptor expression using in vitro and in vivo imaging techniques (positron emission tomography and quantitative autoradiography, respectively). Seventeen male Wistar rats were unilaterally lesioned with 6-hydroxydopamine (6-OHDA) and assigned to two treatment groups 7 weeks later: 10 rats were treated ipsilaterally with an intrastriatal injection of 1 ng BoNT-A, while the others received vehicle (n = 7). All animals were tested for asymmetric motor behavior (apomorphine-induced rotations and forelimb usage) and for striatal expression of dopamine receptors and transporters (D1 R, D2 R, and DAT). The striatal D2 R availability was also quantified longitudinally (1.5, 3, and 5 months after intervention) in 5 animals per treatment group. The 6-OHDA lesion alone induced a unilateral PD-like phenotype and a 13% increase of striatal D2 R. BoNT-A treatment reduced the asymmetry in both apomorphine-induced rotational behavior and D2 R expression, with the latter returning to normal values 5 months after intervention. D1 R expression was significantly reduced, while DAT concentrations showed no alteration. Independent of the treatment, higher interhemispheric symmetry in raclopride binding to D2 R was generally associated with reduced forelimb akinesia. Our findings indicate that striatal BoNT-A treatment diminishes motor impairment and induces changes in D1 and D2 binding site density in the 6-OHDA rat model of PD.
536 _ _ |a 571 - Connectivity and Activity (POF3-571)
|0 G:(DE-HGF)POF3-571
|c POF3-571
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Oskamp, Angela
|0 P:(DE-Juel1)131712
|b 1
700 1 _ |a Lang, Markus
|0 P:(DE-Juel1)131831
|b 2
700 1 _ |a Hawlitschka, Alexander
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Zilles, Karl
|0 P:(DE-Juel1)131714
|b 4
700 1 _ |a Wree, Andreas
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Bauer, Andreas
|0 P:(DE-Juel1)131672
|b 6
773 _ _ |a 10.1002/jnr.24110
|0 PERI:(DE-600)1474904-x
|n 1
|p 75–86
|t Journal of neuroscience research
|v 96
|y 2018
|x 0360-4012
856 4 _ |u https://juser.fz-juelich.de/record/836178/files/JuSER%20-%20Wedekind.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/836178/files/JuSER%20-%20Wedekind.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:836178
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)131711
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)131712
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)131831
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)131714
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)131672
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-571
|2 G:(DE-HGF)POF3-500
|v Connectivity and Activity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2017
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROSCI RES : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-2-20090406
|k INM-2
|l Molekulare Organisation des Gehirns
|x 0
920 1 _ |0 I:(DE-Juel1)INM-1-20090406
|k INM-1
|l Strukturelle und funktionelle Organisation des Gehirns
|x 1
920 1 _ |0 I:(DE-Juel1)INM-5-20090406
|k INM-5
|l Nuklearchemie
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-2-20090406
980 _ _ |a I:(DE-Juel1)INM-1-20090406
980 _ _ |a I:(DE-Juel1)INM-5-20090406
980 _ _ |a APC
980 _ _ |a UNRESTRICTED
980 1 _ |a APC


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21